Kura Oncology (NASDAQ:KURA) Stock Price Expected to Rise, Wedbush Analyst Says

Kura Oncology (NASDAQ:KURA - Free Report) had its price target hoisted by Wedbush from $34.00 to $36.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other analysts have also issued reports on the stock. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a "buy" rating for the company in a research note on Friday, November 22nd. BTIG Research downgraded shares of Kura Oncology from a "buy" rating to a "neutral" rating in a research report on Thursday. JMP Securities reissued a "market outperform" rating and set a $32.00 target price on shares of Kura Oncology in a research report on Tuesday, November 19th. Scotiabank cut their target price on Kura Oncology from $18.00 to $10.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group decreased their price target on Kura Oncology from $32.00 to $28.00 and set a "buy" rating for the company in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $27.13.

Kura Oncology Stock Up 1.6 %

KURA stock traded up $0.14 during mid-day trading on Thursday, reaching $8.79. 1,103,976 shares of the company traded hands, compared to its average volume of 1,885,880. The stock has a market cap of $683.51 million, a price-to-earnings ratio of -3.72 and a beta of 0.78. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The firm's 50 day moving average price is $8.74 and its 200 day moving average price is $14.95. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period in the prior year, the company posted ($0.50) EPS. As a group, equities research analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the company's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now directly owns 88,193 shares of the company's stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares of the company's stock, valued at $694,551.11. The trade was a 5.32 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 12,255 shares of company stock valued at $100,739 over the last ninety days. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of KURA. Suvretta Capital Management LLC raised its holdings in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company's stock valued at $149,535,000 after acquiring an additional 583,155 shares during the period. Alethea Capital Management LLC grew its position in shares of Kura Oncology by 108.2% in the third quarter. Alethea Capital Management LLC now owns 553,542 shares of the company's stock valued at $10,816,000 after purchasing an additional 287,636 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $3,695,000. Wealthfront Advisers LLC bought a new stake in shares of Kura Oncology during the 4th quarter valued at $1,289,000. Finally, Barclays PLC lifted its holdings in Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock worth $3,234,000 after purchasing an additional 84,563 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.